Karyopharm Therapeutics Inc.
KPTI
Rank in Stocks
#33021
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already... Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
Share Price
$0.04
Last synced: 2026-11-09
Market Cap
$907.26K
Change (1 day)
-27.14%
Change (1 year)
-99.28%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Karyopharm Therapeutics Inc. (KPTI)
Category
Healthcare
Operating Margin for Karyopharm Therapeutics Inc. (KPTI)
Operating Margin as of November 2026 TTM: -56.17%
According to Karyopharm Therapeutics Inc.'s latest financial reports, its current operating margin (TTM) is -56.17%. At the end of 2025 the company had an operating margin of -62.10%.
Operating Margin history for Karyopharm Therapeutics Inc. from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -56.17% | -9.55% |
| 2025 | -62.10% | -24.49% |
| 2024 | -82.24% | -7.29% |
| 2023 | -88.71% | -2.01% |
| 2022 | -90.53% | 93.27% |
| 2021 | -46.84% | -70.54% |
| 2020 | -159.00% | -65.65% |
| 2019 | -462.85% | -21.94% |
| 2018 | -592.97% | -92.71% |
| 2017 | -8,133.21% | -88.69% |
| 2016 | -71,903.90% | 50.96% |
| 2015 | -47,630.40% | 43.81% |
| 2014 | -33,120.52% | 277.54% |
| 2013 | -8,772.61% | 250.02% |
| 2012 | -2,506.31% | -63.05% |
| 2011 | -6,783.55% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.69% |
US
|
|
| -149.01% | -97.35% |
US
|
|
| 25.57% | -100.46% |
AU
|
|
| 31.23% | -100.56% |
BE
|
|
| 29.35% | -100.52% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Karyopharm Therapeutics Inc.'s operating margin
What is Karyopharm Therapeutics Inc.'s operating margin?
Karyopharm Therapeutics Inc.'s operating margin is -56.17%, as of Nov 2026.
What was Karyopharm Therapeutics Inc.'s operating margin in 2025?
In 2025, Karyopharm Therapeutics Inc.'s operating margin was -62.10%, compared with -82.24% in 2024.
How has Karyopharm Therapeutics Inc.'s operating margin changed since 2020?
From 2020 to 2025, Karyopharm Therapeutics Inc.'s operating margin was highest in 2021 (-46.84%) and lowest in 2020 (-159.00%).
How does Karyopharm Therapeutics Inc.'s operating margin compare with similar companies?
Karyopharm Therapeutics Inc.'s operating margin (-56.17%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.